Amanda Gollo Bertollo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amanda Gollo Bertollo has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Zuleide Maria Ignácio
Graduate Program in Biomedical Sciences, Laboratory of Physiology, Pharmacology, and Psychopathology, Federal University of Fronteira Sul, Chapecó, SC, Brazil
12 shared publications - Margarete Dulce Bagatini
Graduate Program in Medical Sciences, Federal University of Fronteira Sul, Chapecó 89815-899, SC, Brazil
5 shared publications - Maiqueli Eduarda Dama Mingoti
Laboratório de Fisiologia Farmacologia e Psicopatologia Programa de Pós-graduação em Ciências Biomédicas Universidade Federal da Fronteira Sul (UFFS) Chapecó SC Brasil
4 shared publications - Brunna Varela da Silva
Laboratório de Fisiologia Farmacologia e Psicopatologia Programa de Pós-graduação em Ciências Biomédicas Universidade Federal da Fronteira Sul (UFFS) Chapecó SC Brasil
3 shared publications - Adriana Remião Luzardo
Research Laboratory in Health Management, Innovation and Technologies, Graduate Program in Nursing, Federal University of Fronteira Sul, Chapecó 89815-899, SC, Brazil
2 shared publications - Geórgia de Carvalho Braga
Medical School, Federal University of Fronteira Sul, Chapecó 89815-899, SC, Brazil
2 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (2) , 223
Medicinal Plants for Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe, chronic illness for which conventional treatments often show limited efficacy and side effects, driving a renewed interest in traditional medicinal plants. The therapeutic promise of these plants lies in their multi-targeted action, influencing neurotransmitter systems, modulating neuroinflammation and oxidative stress, impacting neuroplasticity, and regulating the Hypothalamic–Pituitary–Adrenal (HPA) axis. Despite their clinical potential, the use of medicinal plants is associated with challenges, including complex pharmacokinetics, significant adverse effects, and the risk of herb–drug interactions, alongside concerns regarding standardization and quality control. This manuscript aims to examine the therapeutic potential of key medicinal plants for managing MDD, including Hypericum perforatum, Rhodiola rosea, Melissa officinalis, Passiflora incarnata, Valeriana officinalis, and Cannabis sativa. Additionally, the review addresses emerging candidates such as Curcuma longa, Withania somnifera, Panax ginseng and Centella asiatica. By focusing on their mechanisms of action, pharmacokinetics, and associated risks, this review provides a more comprehensive understanding of their role in modern psychiatric care.
- 13 February 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (2) , 223
Open AccessMedicinal Plants for Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe, chronic illness for which conventional treatments often show limited efficacy and side effects, driving a renewed interest in traditional medicinal plants. The therapeutic promise of these plants lies in their multi-targeted action, influencing neurotransmitter systems, modulating neuroinflammation and oxidative stress, impacting neuroplasticity, and regulating the Hypothalamic–Pituitary–Adrenal (HPA) axis. Despite their clinical potential, the use of medicinal plants is associated with challenges, including complex pharmacokinetics, significant adverse effects, and the risk of herb–drug interactions, alongside concerns regarding standardization and quality control. This manuscript aims to examine the therapeutic potential of key medicinal plants for managing MDD, including Hypericum perforatum, Rhodiola rosea, Melissa officinalis, Passiflora incarnata, Valeriana officinalis, and Cannabis sativa. Additionally, the review addresses emerging candidates such as Curcuma longa, Withania somnifera, Panax ginseng and Centella asiatica. By focusing on their mechanisms of action, pharmacokinetics, and associated risks, this review provides a more comprehensive understanding of their role in modern psychiatric care.
- Open Access
- 10 January 2026
- Published by Elsevier in Neuroscience
- Vol. 596, 128-142
Neurobiological and psychosocial mechanisms linking early life stress to the pathogenesis of eating disorders
- 10 January 2026
- Published by Elsevier in Neuroscience
- Vol. 596, 128-142
Open AccessNeurobiological and psychosocial mechanisms linking early life stress to the pathogenesis of eating disorders
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 20, e20250290
Non-pharmacological strategies for the management of Alzheimer's disease
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease affecting various cognitive domains, requiring a holistic and integrated therapeutic approach. The treatment of AD goes beyond pharmacological interventions, also necessitating non-pharmacological therapies that can act synergistically, both with each other and with emerging pharmacological treatments, including new anti-amyloid therapies. These therapies aim to improve patients’ quality of life and alleviate behavioral symptoms, such as agitation and depression, and delay disease progression. Current clinical and meta-analytic evidence suggests that these approaches can be effectively integrated with conventional treatment, offering a valuable alternative to enhance patients’ overall well-being. However, further research is needed to deepen the understanding of the ideal combination of the new anti-amyloid therapies, to address the limitations of current evidence, and to robustly establish their effectiveness in the clinical context of AD, aiming to generate a broader and more lasting impact on disease treatment. This narrative review aims to synthesize the evidence on diverse non-pharmacological therapies for managing AD and discuss their practical implications for clinical care.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 20, e20250290
Open AccessNon-pharmacological strategies for the management of Alzheimer's disease
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease affecting various cognitive domains, requiring a holistic and integrated therapeutic approach. The treatment of AD goes beyond pharmacological interventions, also necessitating non-pharmacological therapies that can act synergistically, both with each other and with emerging pharmacological treatments, including new anti-amyloid therapies. These therapies aim to improve patients’ quality of life and alleviate behavioral symptoms, such as agitation and depression, and delay disease progression. Current clinical and meta-analytic evidence suggests that these approaches can be effectively integrated with conventional treatment, offering a valuable alternative to enhance patients’ overall well-being. However, further research is needed to deepen the understanding of the ideal combination of the new anti-amyloid therapies, to address the limitations of current evidence, and to robustly establish their effectiveness in the clinical context of AD, aiming to generate a broader and more lasting impact on disease treatment. This narrative review aims to synthesize the evidence on diverse non-pharmacological therapies for managing AD and discuss their practical implications for clinical care.
- Open Access
- 18 September 2025
- Published by Associação Brasileira de Estudos da Cannabis sativa in Revista Brasileira de Cannabis
- Vol. 1 (1)
EFEITO DO ESTRESSE NA INFÂNCIA SOBRE COMPORTAMENTOS DEPRESSIVOS NA VIDA ADULTA: POTENCIAL ESTRATÉGIA TERAPÊUTICA DO ÓLEO DE CANNABIS SATIVA DE ESPECTRO COMPLETO
O Transtorno Depressivo Maior (TDM) é uma condição psiquiátrica multifatorial, na qual fatores como estresse crônico e eventos traumáticos resultam em disfunções neurais e sistêmicas. Evidências indicam que adversidades precoces, incluindo privação maternal (PM), comprometem o desenvolvimento cerebral e, quando combinadas ao isolamento social (IS) na vida adulta, aumentam a vulnerabilidade ao desenvolvimento de sintomas depressivos e resistência ao tratamento convencional. As limitações das terapias atuais motivam a investigação de novas abordagens, incluindo compostos vegetais com potencial antidepressivo. Este estudo avaliou o comportamento tipo depressivo e a modulação pelo sistema endocanabinoide em ratos submetidos ao estresse por PM nos primeiros dias de vida, seguido de IS na idade adulta, além de investigar o efeito do tratamento com óleo de Cannabis sativa de espectro completo. Ratos Wistar machos foram distribuídos em quatro grupos experimentais (N=10 por grupo): controle sem estresse + salina; PM+IS + salina; PM+IS + Escitalopram; e PM+IS + óleo de C. sativa de espectro completo. O protocolo de estresse foi seguido de tratamento crônico por 14 dias e posterior avaliação comportamental por meio dos testes de atividade locomotora e natação forçada. Os resultados demonstraram que o grupo PM+IS + salina apresentou um aumento significativo no tempo de imobilidade no teste de natação forçada em comparação ao grupo controle, indicando um fenótipo tipo depressivo. O tratamento com óleo de C. sativa reduziu significativamente o tempo de imobilidade, sugerindo um efeito antidepressivo semelhante ao do Escitalopram. A ausência de diferenças na atividade locomotora sugere que o comportamento do tipo depressivo identificado no teste de nado forçado não foi influenciado por déficits locomotores. Esses achados destacam o potencial terapêutico do óleo de C. sativa no manejo do TDM e reforçam a necessidade de estudos adicionais para elucidar seus mecanismos de ação. Palavras-chave: Transtorno depressivo maior; Privação maternal; Cannabis sativa.
- 18 September 2025
- Published by Associação Brasileira de Estudos da Cannabis sativa in Revista Brasileira de Cannabis
- Vol. 1 (1)
Open AccessEFEITO DO ESTRESSE NA INFÂNCIA SOBRE COMPORTAMENTOS DEPRESSIVOS NA VIDA ADULTA: POTENCIAL ESTRATÉGIA TERAPÊUTICA DO ÓLEO DE CANNABIS SATIVA DE ESPECTRO COMPLETO
O Transtorno Depressivo Maior (TDM) é uma condição psiquiátrica multifatorial, na qual fatores como estresse crônico e eventos traumáticos resultam em disfunções neurais e sistêmicas. Evidências indicam que adversidades precoces, incluindo privação maternal (PM), comprometem o desenvolvimento cerebral e, quando combinadas ao isolamento social (IS) na vida adulta, aumentam a vulnerabilidade ao desenvolvimento de sintomas depressivos e resistência ao tratamento convencional. As limitações das terapias atuais motivam a investigação de novas abordagens, incluindo compostos vegetais com potencial antidepressivo. Este estudo avaliou o comportamento tipo depressivo e a modulação pelo sistema endocanabinoide em ratos submetidos ao estresse por PM nos primeiros dias de vida, seguido de IS na idade adulta, além de investigar o efeito do tratamento com óleo de Cannabis sativa de espectro completo. Ratos Wistar machos foram distribuídos em quatro grupos experimentais (N=10 por grupo): controle sem estresse + salina; PM+IS + salina; PM+IS + Escitalopram; e PM+IS + óleo de C. sativa de espectro completo. O protocolo de estresse foi seguido de tratamento crônico por 14 dias e posterior avaliação comportamental por meio dos testes de atividade locomotora e natação forçada. Os resultados demonstraram que o grupo PM+IS + salina apresentou um aumento significativo no tempo de imobilidade no teste de natação forçada em comparação ao grupo controle, indicando um fenótipo tipo depressivo. O tratamento com óleo de C. sativa reduziu significativamente o tempo de imobilidade, sugerindo um efeito antidepressivo semelhante ao do Escitalopram. A ausência de diferenças na atividade locomotora sugere que o comportamento do tipo depressivo identificado no teste de nado forçado não foi influenciado por déficits locomotores. Esses achados destacam o potencial terapêutico do óleo de C. sativa no manejo do TDM e reforçam a necessidade de estudos adicionais para elucidar seus mecanismos de ação. Palavras-chave: Transtorno depressivo maior; Privação maternal; Cannabis sativa.
- Open Access
- 11 September 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1360
Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder
Purpose: Genetic polymorphisms within specific genes play a role in both the genetic predisposition to Major Depressive Disorder (MDD) and the variation observed in responses to antidepressant treatments. Pharmacogenetics examines how these polymorphisms affect medication response. This review highlights significant disparities in the pharmacogenetic influences on antidepressant response, with a focus on ethnic and sex-based differences. Methods: This review synthesizes findings from a comprehensive literature search conducted between 2000 and 2025. It utilized databases such as PubMed, Scopus, and Web of Science, using search terms including “pharmacogenetics”, “antidepressants”, “Major Depressive Disorder”, “CYP450”, “neuroplasticity”, and “genetic variations”. This review integrates pharmacogenetics with neurotransmitters and their transporters, neuroplasticity, growth factors, and the cytochrome P450 family, providing promising insights for personalized MDD treatment strategies. We analyzed and synthesized findings from over 50 relevant studies, focusing on those with a clear emphasis on genetic associations with antidepressant efficacy and adverse effects. Results: Pharmacogenetic analysis facilitates personalized antidepressant prescriptions by identifying key genetic variants that influence treatment outcomes. Specifically, variations in CYP2D6 and CYP2C19 can significantly impact drug metabolism and tolerability. A high percentage of patients with non-normal metabolizer phenotypes are predisposed to adverse drug reactions or ineffective responses. Furthermore, this review identifies significant ethnic and sex-based disparities in treatment response. For example, the L allele of the 5-HTTLPR polymorphism confers a higher likelihood of response and remission following SSRI treatment in white people compared to Asians. Additionally, in women, specific 5-HTTLPR polymorphisms have a more pronounced influence on mood and MDD pathophysiology, with a significant reduction in mood in response to tryptophan depletion. Conclusions: Integrating pharmacogenetic insights, encompassing genetic factors, neurotransmitter pathways, neuroplasticity, and the influence of ethnicity and sex, is crucial for developing personalized antidepressant treatment strategies. This will ultimately optimize patient recovery and minimize adverse effects.
- 11 September 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1360
Open AccessPharmacogenetics and the Response to Antidepressants in Major Depressive Disorder
Purpose: Genetic polymorphisms within specific genes play a role in both the genetic predisposition to Major Depressive Disorder (MDD) and the variation observed in responses to antidepressant treatments. Pharmacogenetics examines how these polymorphisms affect medication response. This review highlights significant disparities in the pharmacogenetic influences on antidepressant response, with a focus on ethnic and sex-based differences. Methods: This review synthesizes findings from a comprehensive literature search conducted between 2000 and 2025. It utilized databases such as PubMed, Scopus, and Web of Science, using search terms including “pharmacogenetics”, “antidepressants”, “Major Depressive Disorder”, “CYP450”, “neuroplasticity”, and “genetic variations”. This review integrates pharmacogenetics with neurotransmitters and their transporters, neuroplasticity, growth factors, and the cytochrome P450 family, providing promising insights for personalized MDD treatment strategies. We analyzed and synthesized findings from over 50 relevant studies, focusing on those with a clear emphasis on genetic associations with antidepressant efficacy and adverse effects. Results: Pharmacogenetic analysis facilitates personalized antidepressant prescriptions by identifying key genetic variants that influence treatment outcomes. Specifically, variations in CYP2D6 and CYP2C19 can significantly impact drug metabolism and tolerability. A high percentage of patients with non-normal metabolizer phenotypes are predisposed to adverse drug reactions or ineffective responses. Furthermore, this review identifies significant ethnic and sex-based disparities in treatment response. For example, the L allele of the 5-HTTLPR polymorphism confers a higher likelihood of response and remission following SSRI treatment in white people compared to Asians. Additionally, in women, specific 5-HTTLPR polymorphisms have a more pronounced influence on mood and MDD pathophysiology, with a significant reduction in mood in response to tryptophan depletion. Conclusions: Integrating pharmacogenetic insights, encompassing genetic factors, neurotransmitter pathways, neuroplasticity, and the influence of ethnicity and sex, is crucial for developing personalized antidepressant treatment strategies. This will ultimately optimize patient recovery and minimize adverse effects.
- Top Cited PapersOpen Access
- 14 March 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (3) , 307
Neurobiological Relationships Between Neurodevelopmental Disorders and Mood Disorders
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), neurodevelopmental disorders (NDDs) are a group of conditions that arise early in development and are characterized by deficits in personal, social, academic, or occupational functioning. These disorders frequently co-occur and include conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Mood disorders (MDs), such as major depressive disorder and bipolar disorder, also pose significant global health challenges due to their high prevalence and substantial impact on quality of life. Emerging evidence highlights overlapping neurobiological mechanisms between NDDs and MDs, including shared genetic susceptibilities, neurotransmitter dysregulation (e.g., dopaminergic and serotonergic pathways), neuroinflammation, and hypothalamic–pituitary–adrenal (HPA) axis dysfunction. Environmental factors such as early-life adversity further exacerbate these vulnerabilities, contributing to the complexity of their clinical presentation and comorbidity. Functional neuroimaging studies reveal altered connectivity in brain regions critical for emotional regulation and executive function, such as the prefrontal cortex and amygdala, across these disorders. Despite these advances, integrative diagnostic frameworks and targeted therapeutic strategies remain underexplored, limiting effective intervention. This review synthesizes current knowledge on the shared neurobiological underpinnings of NDDs and MDs, emphasizing the need for multidisciplinary research, including genetic, pharmacological, and psychological approaches, for unified diagnosis and treatment. Addressing these intersections can improve clinical outcomes and enhance the quality of life for individuals affected by these disorders.
- 14 March 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (3) , 307
Top Cited PapersOpen AccessNeurobiological Relationships Between Neurodevelopmental Disorders and Mood Disorders
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), neurodevelopmental disorders (NDDs) are a group of conditions that arise early in development and are characterized by deficits in personal, social, academic, or occupational functioning. These disorders frequently co-occur and include conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Mood disorders (MDs), such as major depressive disorder and bipolar disorder, also pose significant global health challenges due to their high prevalence and substantial impact on quality of life. Emerging evidence highlights overlapping neurobiological mechanisms between NDDs and MDs, including shared genetic susceptibilities, neurotransmitter dysregulation (e.g., dopaminergic and serotonergic pathways), neuroinflammation, and hypothalamic–pituitary–adrenal (HPA) axis dysfunction. Environmental factors such as early-life adversity further exacerbate these vulnerabilities, contributing to the complexity of their clinical presentation and comorbidity. Functional neuroimaging studies reveal altered connectivity in brain regions critical for emotional regulation and executive function, such as the prefrontal cortex and amygdala, across these disorders. Despite these advances, integrative diagnostic frameworks and targeted therapeutic strategies remain underexplored, limiting effective intervention. This review synthesizes current knowledge on the shared neurobiological underpinnings of NDDs and MDs, emphasizing the need for multidisciplinary research, including genetic, pharmacological, and psychological approaches, for unified diagnosis and treatment. Addressing these intersections can improve clinical outcomes and enhance the quality of life for individuals affected by these disorders.
- Open Access
- 4 February 2025
- Published by MDPI AG in Preprints.org
Neurobiological Relationships Between Neurodevelopmental Disorders and Mood Disorders
Neurodevelopmental disorders (NDDs), such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), and mood disorders (MDs), including major depressive disorder and bipolar disorder, present significant global health challenges due to their high prevalence and profound impact on quality of life. Emerging evidence highlights overlapping neurobiological mechanisms between NDDs and MDs, including shared genetic susceptibilities, neurotransmitter dysregulation (e.g., dopaminergic and serotonergic pathways), neuroinflammation, and hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Environmental factors, such as early-life adversity, further exacerbate these vulnerabilities, contributing to the complexity of their clinical presentation and comorbidity. Functional neuroimaging studies reveal altered connectivity in brain regions critical for emotional regulation and executive function, such as the prefrontal cortex and amygdala, across these disorders. Despite these advances, integrative diagnostic frameworks and targeted therapeutic strategies remain underexplored, limiting effective intervention. This review synthesizes current knowledge on the shared neurobiological underpinnings of NDDs and MDs, emphasizing the need for multidisciplinary research to develop unified approaches for diagnosis and treatment. Addressing these intersections can improve clinical outcomes and enhance the quality of life for individuals affected by these disorders.
- 4 February 2025
- Published by MDPI AG in Preprints.org
Open AccessNeurobiological Relationships Between Neurodevelopmental Disorders and Mood Disorders
Neurodevelopmental disorders (NDDs), such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), and mood disorders (MDs), including major depressive disorder and bipolar disorder, present significant global health challenges due to their high prevalence and profound impact on quality of life. Emerging evidence highlights overlapping neurobiological mechanisms between NDDs and MDs, including shared genetic susceptibilities, neurotransmitter dysregulation (e.g., dopaminergic and serotonergic pathways), neuroinflammation, and hypothalamic-pituitary-adrenal (HPA) axis dysfunction. Environmental factors, such as early-life adversity, further exacerbate these vulnerabilities, contributing to the complexity of their clinical presentation and comorbidity. Functional neuroimaging studies reveal altered connectivity in brain regions critical for emotional regulation and executive function, such as the prefrontal cortex and amygdala, across these disorders. Despite these advances, integrative diagnostic frameworks and targeted therapeutic strategies remain underexplored, limiting effective intervention. This review synthesizes current knowledge on the shared neurobiological underpinnings of NDDs and MDs, emphasizing the need for multidisciplinary research to develop unified approaches for diagnosis and treatment. Addressing these intersections can improve clinical outcomes and enhance the quality of life for individuals affected by these disorders.
- 10 January 2025
- Published by Taylor & Francis in Biological Rhythm Research
- Vol. 56 (4) , 291-304
Biological rhythms and psychiatric symptoms in COVID-19 individuals: a cross-sectional multicentric study
- 10 January 2025
- Published by Taylor & Francis in Biological Rhythm Research
- Vol. 56 (4) , 291-304
Biological rhythms and psychiatric symptoms in COVID-19 individuals: a cross-sectional multicentric study
- 9 September 2024
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 36 (2) , 169-187
Neurobiological mechanisms in the kynurenine pathway and major depressive disorder
Major depressive disorder (MDD) is a prevalent psychiatric disorder that has damage to people’s quality of life. Tryptophan is the precursor to serotonin, a critical neurotransmitter in mood modulation. In mammals, most free tryptophan is degraded by the kynurenine pathway (KP), resulting in a range of metabolites involved in inflammation, immune response, and neurotransmission. The imbalance between quinolinic acid (QA), a toxic metabolite, and kynurenic acid (KynA), a protective metabolite, is a relevant phenomenon involved in the pathophysiology of MDD. Proinflammatory cytokines increase the activity of the enzyme indoleamine 2,3-dioxygenase (IDO), leading to the degradation of tryptophan in the KP and an increase in the release of QA. IDO activates proinflammatory genes, potentiating neuroinflammation and deregulating other physiological mechanisms related to chronic stress and MDD. This review highlights the physiological mechanisms involved with stress and MDD, which are underlying an imbalance of the KP and discuss potential therapeutic targets.
- 9 September 2024
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 36 (2) , 169-187
Neurobiological mechanisms in the kynurenine pathway and major depressive disorder
Major depressive disorder (MDD) is a prevalent psychiatric disorder that has damage to people’s quality of life. Tryptophan is the precursor to serotonin, a critical neurotransmitter in mood modulation. In mammals, most free tryptophan is degraded by the kynurenine pathway (KP), resulting in a range of metabolites involved in inflammation, immune response, and neurotransmission. The imbalance between quinolinic acid (QA), a toxic metabolite, and kynurenic acid (KynA), a protective metabolite, is a relevant phenomenon involved in the pathophysiology of MDD. Proinflammatory cytokines increase the activity of the enzyme indoleamine 2,3-dioxygenase (IDO), leading to the degradation of tryptophan in the KP and an increase in the release of QA. IDO activates proinflammatory genes, potentiating neuroinflammation and deregulating other physiological mechanisms related to chronic stress and MDD. This review highlights the physiological mechanisms involved with stress and MDD, which are underlying an imbalance of the KP and discuss potential therapeutic targets.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 23 (1) , 122-133
Impact of COVID-19 on Anxiety and Depression - Biopsychosocial Factors
Anxiety and depression are prevalent mental disorders around the world. The etiology of both diseases is multifactorial, involving biological and psychological issues. The COVID-19 pandemic settled in 2020 and culminated in several changes in the routine of individuals around the world, affecting mental health. People infected with COVID-19 are at greater risk of developing anxiety and depression, and individuals previously affected by these disorders have worsened the condition. In addition, individuals diagnosed with anxiety or depression before being affected by COVID-19 developed the severe illness at higher rates than individuals without mental disorders. This harmful cycle involves several mechanisms, including systemic hyper-inflammation and neuroinflammation. Furthermore, the context of the pandemic and some previous psychosocial factors can aggravate or trigger anxiety and depression. Disorders are also risks for a more severe picture of COVID-19. This review discusses research on a scientific basis, which brings evidence on biopsychosocial factors from COVID-19 and the context of the pandemic involved in anxiety and depression disorders.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 23 (1) , 122-133
Impact of COVID-19 on Anxiety and Depression - Biopsychosocial Factors
Anxiety and depression are prevalent mental disorders around the world. The etiology of both diseases is multifactorial, involving biological and psychological issues. The COVID-19 pandemic settled in 2020 and culminated in several changes in the routine of individuals around the world, affecting mental health. People infected with COVID-19 are at greater risk of developing anxiety and depression, and individuals previously affected by these disorders have worsened the condition. In addition, individuals diagnosed with anxiety or depression before being affected by COVID-19 developed the severe illness at higher rates than individuals without mental disorders. This harmful cycle involves several mechanisms, including systemic hyper-inflammation and neuroinflammation. Furthermore, the context of the pandemic and some previous psychosocial factors can aggravate or trigger anxiety and depression. Disorders are also risks for a more severe picture of COVID-19. This review discusses research on a scientific basis, which brings evidence on biopsychosocial factors from COVID-19 and the context of the pandemic involved in anxiety and depression disorders.